Targeting RAF dimers in RAS mutant tumors: From biology to clinic
RAS mutations occur in approximately 30% of tumors worldwide and have a poor prognosis due to limited therapies. Covalent targeting of KRAS G12C has achieved significant success in recent years, but there is still a lack of efficient therapeutic approaches for tumors with non-G12C KRAS mutations. A...
שמור ב:
| Principais autores: | , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Elsevier
2024-05-01
|
| סדרה: | Acta Pharmaceutica Sinica B |
| נושאים: | |
| גישה מקוונת: | http://www.sciencedirect.com/science/article/pii/S221138352400056X |
| תגים: |
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|